Lompat ke isi utama
Main navigation
Tentang HIPRA
Tentang HIPRA
Jelajahi HIPRA
Sejarah
Lingkungan, Masyarakat dan Tata Kelola
HIPRA di seluruh dunia
Kesehatan Hewan
Kesehatan Manusia
Kesehatan Manusia
Bidang Terapeutik
Proyek penelitian & pengembangan
Pengetahuan
Omicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results
Berita
Pers
Karier
Hubungi kami
Select your language
English
Español
Català
Português
Français
Italiano
Deutsch
Nederlands
Dansk
Polski
Türkçe
Ελληνικά
Русский
中文
한국어
Tiếng Việt
ไทย
Bahasa Indonesia
到台灣人
Cari
Negara
Global
Afganistan
Afrika Selatan
Albania
Aljazair
Amerika Serikat
Angola
Arab Saudi
Argentina
Armenia
Australia
Austria
Bahrain
Banglades
Belanda
Belarusia
Belgia
Benin
Bolivia
Bosnia-Herzegovina
Boswana
Brasil
Bulgaria
Burkina Faso
Burundi
Cile
Cina
Denmark
Ekuador
El Salvador
Eritrea
Estonia
Filipina
Finlandia
Georgia
Ghana
Guatemala
Guinea
Honduras
Hong Kong
Hongaria
India
Indonesia
Inggris
Iran
Irlandia
Islandia
Israel
Italia
Jepang
Jerman
Kamboja
Kamerun
Kanada
Kenya
Kolombia
Kongo (Brazzaville)
Kongo (Kinshasa)
Korea Selatan
Kosta Rika
Kroasia
Kuba
Kuwait
Laos
Latvia
Lebanon
Libia
Lichtenstein
Lituania
Luksemburg
Madagaskar
Makedonia
Malaysia
Mali
Malta
Maroko
Mauritania
Mauritius
Meksiko
Mesir
Mozambik
Myanmar
Nepal
Nigeria
Nikaragua
Norwegia
Oman
Pakistan
Panama
Pantai Gading
Paraguay
Peru
Polandia
Portugal
Prancis
Qatar
Republik Ceko
Republik Dominika
Rumania
Rusia
Rwanda
Selandia Baru
Senegal
Serbia
Singapura
Siprus
Slovenia
Slowakia
Spanyol
Sri Lanka
Sudan
Suriah
Swedia
Swiss
Taiwan
Tanzania
Tunisia
Turki
Uganda
Ukraina
Uni Emirat Arab
Uruguay
Usbekistan
Venezuela
Vietnam
Yaman
Yordania
Yunani
Zimbabwe
Kirim
Select your language
Bahasa Inggris
Bahasa Spanyol
Català
Português
Français
Italiano
Deutsch
Nederlands
Dansk
Polski
Türkçe
Ελληνικά
Русский
中文
한국어
Tiếng Việt
ไทย
Bahasa Indonesia
到台灣人
Cari
Negara
Global
Afganistan
Afrika Selatan
Albania
Aljazair
Amerika Serikat
Angola
Arab Saudi
Argentina
Armenia
Australia
Austria
Bahrain
Banglades
Belanda
Belarusia
Belgia
Benin
Bolivia
Bosnia-Herzegovina
Boswana
Brasil
Bulgaria
Burkina Faso
Burundi
Cile
Cina
Denmark
Ekuador
El Salvador
Eritrea
Estonia
Filipina
Finlandia
Georgia
Ghana
Guatemala
Guinea
Honduras
Hong Kong
Hongaria
India
Indonesia
Inggris
Iran
Irlandia
Islandia
Israel
Italia
Jepang
Jerman
Kamboja
Kamerun
Kanada
Kenya
Kolombia
Kongo (Brazzaville)
Kongo (Kinshasa)
Korea Selatan
Kosta Rika
Kroasia
Kuba
Kuwait
Laos
Latvia
Lebanon
Libia
Lichtenstein
Lituania
Luksemburg
Madagaskar
Makedonia
Malaysia
Mali
Malta
Maroko
Mauritania
Mauritius
Meksiko
Mesir
Mozambik
Myanmar
Nepal
Nigeria
Nikaragua
Norwegia
Oman
Pakistan
Panama
Pantai Gading
Paraguay
Peru
Polandia
Portugal
Prancis
Qatar
Republik Ceko
Republik Dominika
Rumania
Rusia
Rwanda
Selandia Baru
Senegal
Serbia
Singapura
Siprus
Slovenia
Slowakia
Spanyol
Sri Lanka
Sudan
Suriah
Swedia
Swiss
Taiwan
Tanzania
Tunisia
Turki
Uganda
Ukraina
Uni Emirat Arab
Uruguay
Usbekistan
Venezuela
Vietnam
Yaman
Yordania
Yunani
Zimbabwe
Kirim
Pencarian
Pencarian
Pers
Beranda
Kesehatan Manusia
Pers
06/26/2024 - 15:09
Significant advancements and a fifteen-month extension for the RBDCOV Project
Manusia
Jelajahi
10/18/2023 - 16:14
BIMERVAX® becomes the first COVID-19 vaccine approved by WHO
Manusia
Jelajahi
07/17/2023 - 14:43
AEMPS authorizes the clinical trial to study the joint vaccination of HIPRA's COVID-19 vaccine with an influenza vaccine
Manusia
Jelajahi
05/29/2023 - 08:15
AEMPS authorizes the clinical trial to study HIPRA's COVID-19 vaccine in adolescents between 12 and 17 years old
Manusia
Jelajahi
04/11/2023 - 16:57
The Spanish Prime Minister defines HIPRA’s vaccine as a 'historic milestone' that reinforces the country's leadership in the European health sector
Manusia
Jelajahi
03/31/2023 - 14:27
BIMERVAX® has also obtained the approval of the European Commission to be marketed
Manusia
Jelajahi
Muat lebih banyak
